HL Financial Services’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

HL Financial Services’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-11,600	Closed	-$147K	–	715
2017 Q3	$147K	Sell	11,600 -5,000	-30%	-$63.6K	﹤0.01%	669
2017 Q2	$197K	Sell	16,600 -6,700	-29%	-$83.3K	﹤0.01%	658
2017 Q1	$344K	Buy	23,300 +2,400	+11%	+$38.9K	0.01%	528
2016 Q4	$338K	Buy	20,900 +10,100	+94%	+$183K	0.01%	530
2016 Q3	$196K	Buy	+10,800	New	+$211K	﹤0.01%	629

Other funds holding HZNP

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HL Financial Services's HZNP Position: Q4 2017 in Review

HL Financial Services sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2017, closing a stake of 11,600 shares — an estimated $147K sold.

HL Financial Services first reported a position in HZNP in Q3 2016 and held it in 5 quarters. The position peaked at $344K in Q1 2017. 183 funds tracked by Wall St. Rank hold HZNP as of Q4 2017.

HL Financial Services reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2017 after selling out during the quarter.
HL Financial Services sold 11,600 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2017, an estimated $147K.
HL Financial Services first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and held it in 5 quarters.
HL Financial Services's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $344K in Q1 2017.
183 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2017.

Based on HL Financial Services's 13F filing for Q4 2017, filed 1 Feb 2018.